APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted RNA Sequencing

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.

In the report, we only collect information about the companies who can provide targeted RNA sequencing service.

Selected research

Market Outlook & Growth Opportunities

Global Targeted RNA Sequencing Market Outlook and Growth Opportunities 2026

21 December 2025195 pages

Choose your research edition.

Industry ResearchTargeted RNA Sequencing Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted RNA Sequencing Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Targeted RNA Sequencing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted RNA Sequencing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted RNA Sequencing Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Targeted RNA-sequencing (RNA-Seq) is a highly accurate method for selecting and sequencing specific transcripts of interest and offers both quantitative and qualitative information. Targeted RNA-Seq can be achieved via either enrichment or amplicon-based approaches, both of which enable gene expression analysis in a focused set of genes of interest, with enrichment assays also providing the ability to detect both known and novel gene fusion partners in many sample types.

In the report, we only collect information about the companies who can provide targeted RNA sequencing service.

Market competition is not intense. Thermo Fisher, Illumina, Roche Holdings, BGI, Eurofins, etc. are the leaders of the industry, with about 52% market shares.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 32%. Following North America, Europe is the second largest consumption place with the consumption market share of 28%.

This report provides an overview of the global Targeted RNA Sequencing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeted RNA Sequencing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeted RNA Sequencing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Targeted RNA Sequencing market.

Targeted RNA Sequencing Segment by Company

Thermo Fisher

Illumina

Roche Holdings

BGI

Eurofins

LabCorp

Berry Genomics

Macrogen

GENEWIZ

Targeted RNA Sequencing Segment by Type

Exome Sequencing

Enrichment Sequencing

Amplicon Sequencing

Targeted RNA Sequencing Segment by Application

Research Institutes

Hospitals & Clinics

Biotechnology Company

Diagnostic Lab

Targeted RNA Sequencing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Targeted RNA Sequencing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Targeted RNA Sequencing key companies, revenue, market share, and recent developments.

3. To split the Targeted RNA Sequencing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Targeted RNA Sequencing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeted RNA Sequencing significant trends, drivers, influence factors in global and regions.

6. To analyze Targeted RNA Sequencing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted RNA Sequencing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted RNA Sequencing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted RNA Sequencing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted RNA Sequencing industry.

Chapter 3: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Targeted RNA Sequencing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeted RNA Sequencing Industry Trends Table 2. Targeted RNA Sequencing Industry Drivers Table 3. Targeted RNA Sequencing Industry Opportunities and Challenges Table 4. Targeted RNA Sequencing Industry Restraints Table 5. Global Targeted RNA Sequencing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeted RNA Sequencing Revenue Share by Company (2021-2026) Table 7. Global Targeted RNA Sequencing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Targeted RNA Sequencing Key Company Manufacturing Base & Headquarters Table 9. Global Targeted RNA Sequencing Company, Product Type & Application Table 10. Global Targeted RNA Sequencing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Targeted RNA Sequencing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Exome Sequencing Table 15. Significant Companies of Enrichment Sequencing Table 16. Significant Companies of Amplicon Sequencing Table 17. Global Targeted RNA Sequencing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Targeted RNA Sequencing Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Targeted RNA Sequencing Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Targeted RNA Sequencing Sales Value Share by Type (2021-2026) Table 21. Global Targeted RNA Sequencing Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Research Institutes Table 23. Significant Companies of Hospitals & Clinics Table 24. Significant Companies of Biotechnology Company Table 25. Significant Companies of Diagnostic Lab Table 26. Global Targeted RNA Sequencing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Targeted RNA Sequencing Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Targeted RNA Sequencing Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Targeted RNA Sequencing Sales Value Share by Application (2021-2026) Table 30. Global Targeted RNA Sequencing Sales Value Share by Application (2027-2032) Table 31. Global Targeted RNA Sequencing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Targeted RNA Sequencing Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Targeted RNA Sequencing Sales Value Share by Region (2021-2026) Table 34. Global Targeted RNA Sequencing Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Targeted RNA Sequencing Sales Value Share by Region (2027-2032) Table 36. Global Targeted RNA Sequencing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Targeted RNA Sequencing Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Targeted RNA Sequencing Sales Value Market Share by Country (2021-2026) Table 39. Global Targeted RNA Sequencing Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Targeted RNA Sequencing Sales Value Market Share by Country (2027-2032) Table 41. Thermo Fisher Company Information Table 42. Thermo Fisher Business Overview Table 43. Thermo Fisher Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Thermo Fisher Targeted RNA Sequencing Product Portfolio Table 45. Thermo Fisher Recent Development Table 46. Illumina Company Information Table 47. Illumina Business Overview Table 48. Illumina Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Illumina Targeted RNA Sequencing Product Portfolio Table 50. Illumina Recent Development Table 51. Roche Holdings Company Information Table 52. Roche Holdings Business Overview Table 53. Roche Holdings Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Roche Holdings Targeted RNA Sequencing Product Portfolio Table 55. Roche Holdings Recent Development Table 56. BGI Company Information Table 57. BGI Business Overview Table 58. BGI Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. BGI Targeted RNA Sequencing Product Portfolio Table 60. BGI Recent Development Table 61. Eurofins Company Information Table 62. Eurofins Business Overview Table 63. Eurofins Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Eurofins Targeted RNA Sequencing Product Portfolio Table 65. Eurofins Recent Development Table 66. LabCorp Company Information Table 67. LabCorp Business Overview Table 68. LabCorp Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. LabCorp Targeted RNA Sequencing Product Portfolio Table 70. LabCorp Recent Development Table 71. Berry Genomics Company Information Table 72. Berry Genomics Business Overview Table 73. Berry Genomics Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Berry Genomics Targeted RNA Sequencing Product Portfolio Table 75. Berry Genomics Recent Development Table 76. Macrogen Company Information Table 77. Macrogen Business Overview Table 78. Macrogen Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Macrogen Targeted RNA Sequencing Product Portfolio Table 80. Macrogen Recent Development Table 81. GENEWIZ Company Information Table 82. GENEWIZ Business Overview Table 83. GENEWIZ Targeted RNA Sequencing Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GENEWIZ Targeted RNA Sequencing Product Portfolio Table 85. GENEWIZ Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Targeted RNA Sequencing Product Image Figure 2. Global Targeted RNA Sequencing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted RNA Sequencing Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeted RNA Sequencing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Exome Sequencing Image Figure 8. Enrichment Sequencing Image Figure 9. Amplicon Sequencing Image Figure 10. Global Targeted RNA Sequencing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Targeted RNA Sequencing Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Targeted RNA Sequencing Sales Value Share by Type (2021-2032) Figure 13. Research Institutes Image Figure 14. Hospitals & Clinics Image Figure 15. Biotechnology Company Image Figure 16. Diagnostic Lab Image Figure 17. Global Targeted RNA Sequencing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Targeted RNA Sequencing Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Targeted RNA Sequencing Sales Value Share by Application (2021-2032) Figure 20. Global Targeted RNA Sequencing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Targeted RNA Sequencing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Targeted RNA Sequencing Sales Value (2021-2032) & (US$ Million) Figure 23. North America Targeted RNA Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Targeted RNA Sequencing Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Targeted RNA Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Targeted RNA Sequencing Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Targeted RNA Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Targeted RNA Sequencing Sales Value (2021-2032) & (US$ Million) Figure 29. South America Targeted RNA Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Targeted RNA Sequencing Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Targeted RNA Sequencing Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Targeted RNA Sequencing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Exome Sequencing
  • Enrichment Sequencing
  • Amplicon Sequencing
Applications
  • Research Institutes
  • Hospitals & Clinics
  • Biotechnology Company
  • Diagnostic Lab
Companies covered
  • Thermo Fisher
  • Illumina
  • Roche Holdings
  • BGI
  • Eurofins
  • LabCorp
  • Berry Genomics
  • Macrogen
  • GENEWIZ

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeted RNA Sequencing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeted RNA Sequencing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Targeted RNA Sequencing Market Dynamics
  1. 2.1 Targeted RNA Sequencing Industry Trends
  2. 2.2 Targeted RNA Sequencing Industry Drivers
  3. 2.3 Targeted RNA Sequencing Industry Opportunities and Challenges
  4. 2.4 Targeted RNA Sequencing Industry Restraints
3 Targeted RNA Sequencing Market by Company
  1. 3.1 Global Targeted RNA Sequencing Company Revenue Ranking in 2025
  2. 3.2 Global Targeted RNA Sequencing Revenue by Company (2021-2026)
  3. 3.3 Global Targeted RNA Sequencing Company Ranking (2024-2026)
  4. 3.4 Global Targeted RNA Sequencing Company Manufacturing Base and Headquarters
  5. 3.5 Global Targeted RNA Sequencing Company Product Type and Application
  6. 3.6 Global Targeted RNA Sequencing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Targeted RNA Sequencing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Targeted RNA Sequencing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Targeted RNA Sequencing Market by Type
  1. 4.1 Targeted RNA Sequencing Type Introduction
  2. 4.1.1 Exome Sequencing
  3. 4.1.2 Enrichment Sequencing
  4. 4.1.3 Amplicon Sequencing
  5. 4.2 Global Targeted RNA Sequencing Sales Value by Type
  6. 4.2.1 Global Targeted RNA Sequencing Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Targeted RNA Sequencing Sales Value by Type (2021-2032)
  8. 4.2.3 Global Targeted RNA Sequencing Sales Value Share by Type (2021-2032)
5 Targeted RNA Sequencing Market by Application
  1. 5.1 Targeted RNA Sequencing Application Introduction
  2. 5.1.1 Research Institutes
  3. 5.1.2 Hospitals & Clinics
  4. 5.1.3 Biotechnology Company
  5. 5.1.4 Diagnostic Lab
  6. 5.2 Global Targeted RNA Sequencing Sales Value by Application
  7. 5.2.1 Global Targeted RNA Sequencing Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Targeted RNA Sequencing Sales Value by Application (2021-2032)
  9. 5.2.3 Global Targeted RNA Sequencing Sales Value Share by Application (2021-2032)
6 Targeted RNA Sequencing Regional Value Analysis
  1. 6.1 Global Targeted RNA Sequencing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeted RNA Sequencing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Targeted RNA Sequencing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Targeted RNA Sequencing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeted RNA Sequencing Sales Value (2021-2032)
  7. 6.3.2 North America Targeted RNA Sequencing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Targeted RNA Sequencing Sales Value (2021-2032)
  10. 6.4.2 Europe Targeted RNA Sequencing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Targeted RNA Sequencing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Targeted RNA Sequencing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Targeted RNA Sequencing Sales Value (2021-2032)
  16. 6.6.2 South America Targeted RNA Sequencing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Targeted RNA Sequencing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Targeted RNA Sequencing Sales Value Share by Country, 2025 VS 2032
7 Targeted RNA Sequencing Country-level Value Analysis
  1. 7.1 Global Targeted RNA Sequencing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeted RNA Sequencing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Targeted RNA Sequencing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Targeted RNA Sequencing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Targeted RNA Sequencing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Targeted RNA Sequencing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Targeted RNA Sequencing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher
  2. 8.1.1 Thermo Fisher Company Information
  3. 8.1.2 Thermo Fisher Business Overview
  4. 8.1.3 Thermo Fisher Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Targeted RNA Sequencing Product Portfolio
  6. 8.1.5 Thermo Fisher Recent Developments
  7. 8.2 Illumina
  8. 8.2.1 Illumina Company Information
  9. 8.2.2 Illumina Business Overview
  10. 8.2.3 Illumina Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Illumina Targeted RNA Sequencing Product Portfolio
  12. 8.2.5 Illumina Recent Developments
  13. 8.3 Roche Holdings
  14. 8.3.1 Roche Holdings Company Information
  15. 8.3.2 Roche Holdings Business Overview
  16. 8.3.3 Roche Holdings Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Holdings Targeted RNA Sequencing Product Portfolio
  18. 8.3.5 Roche Holdings Recent Developments
  19. 8.4 BGI
  20. 8.4.1 BGI Company Information
  21. 8.4.2 BGI Business Overview
  22. 8.4.3 BGI Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BGI Targeted RNA Sequencing Product Portfolio
  24. 8.4.5 BGI Recent Developments
  25. 8.5 Eurofins
  26. 8.5.1 Eurofins Company Information
  27. 8.5.2 Eurofins Business Overview
  28. 8.5.3 Eurofins Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eurofins Targeted RNA Sequencing Product Portfolio
  30. 8.5.5 Eurofins Recent Developments
  31. 8.6 LabCorp
  32. 8.6.1 LabCorp Company Information
  33. 8.6.2 LabCorp Business Overview
  34. 8.6.3 LabCorp Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 LabCorp Targeted RNA Sequencing Product Portfolio
  36. 8.6.5 LabCorp Recent Developments
  37. 8.7 Berry Genomics
  38. 8.7.1 Berry Genomics Company Information
  39. 8.7.2 Berry Genomics Business Overview
  40. 8.7.3 Berry Genomics Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Berry Genomics Targeted RNA Sequencing Product Portfolio
  42. 8.7.5 Berry Genomics Recent Developments
  43. 8.8 Macrogen
  44. 8.8.1 Macrogen Company Information
  45. 8.8.2 Macrogen Business Overview
  46. 8.8.3 Macrogen Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Macrogen Targeted RNA Sequencing Product Portfolio
  48. 8.8.5 Macrogen Recent Developments
  49. 8.9 GENEWIZ
  50. 8.9.1 GENEWIZ Company Information
  51. 8.9.2 GENEWIZ Business Overview
  52. 8.9.3 GENEWIZ Targeted RNA Sequencing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GENEWIZ Targeted RNA Sequencing Product Portfolio
  54. 8.9.5 GENEWIZ Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst